PLRZ

Business Context and Reporting Period

Polyrizon Ltd. (Nasdaq: PLRZ) is an Israeli clinical-stage biotechnology company developing nasal hydrogel technologies. The company operates two primary platforms: Capture & Contain (C&C), a physical barrier against viruses and allergens (e.g., NASARIX™ for allergies, PL-16 for influenza), and Trap & Target (T&T), a drug delivery system for intranasal administration of APIs (e.g., naloxone, benzodiazepines). The reporting period covers the fiscal year ended December 31, 2025. The company is classified as an Emerging Growth Company and a Foreign Private Issuer.

Key Financial Metrics

Note: Share counts reflect retroactive adjustments for a 1-for-250 reverse split (May 2025) and a 1-for-6 reverse split (November 2025).

Material Changes vs. Prior Period

• Capital Raising: The company raised approximately $22 million in 2025 through a March private placement ($17 million gross) and a December registered direct offering ($4.97 million gross). This significantly increased total assets and bank deposits.
• Operating Expenses: Operating loss increased by 380% to $6.2 million. Research and Development (R&D) expenses rose to $2.1 million (from $0.5 million), and General and Administrative (G&A) expenses surged to $4.1 million (from $0.8 million).
• Unusual Items: G&A expenses included a $464,000 charge related to a Business Email Compromise (BEC) fraud incident in October 2025, where funds were transferred to unauthorized accounts.
• Financial Income: Net financing income of $2.9 million in 2025 (vs. $0.2 million expense in 2024) was driven primarily by a $5.1 million fair value revaluation gain on derivative warrant liabilities following the exercise of warrants.
• Intangible Assets: The company recognized a $37,000 impairment loss on its SciSparc license intangible asset due to market price reductions.

Guidance, Outlook, and Risks

Outlook and Milestones:

• NASARIX™ (Allergies): Pivotal clinical trials are expected to commence in Q3 2026, with FDA 510(k) clearance anticipated thereafter.
• PL-16 (Influenza): Feasibility trials planned for Q3 2027; pivotal trials for Q3 2028 via De Novo pathway.
• T&T Platform: Feasibility studies for naloxone and benzodiazepines are ongoing through 2026, with Phase I trials planned for late 2028.

Liquidity: Management believes existing cash and bank deposits ($17.5 million total) are sufficient to fund operations through March 2030.

Key Risks:

• Geopolitical Instability: Operations are based in Israel. The filing highlights ongoing military conflicts involving Iran, Hezbollah, and Hamas, which pose risks to operations, personnel, and the broader Israeli economy.
• Cybersecurity: The October 2025 BEC fraud resulted in a $464,000 loss. While remediated, the risk of future cyber-attacks remains a material concern.
• Regulatory Uncertainty: Success depends on FDA and EU regulatory pathways (510(k), De Novo, 505(b)(2)). Delays or rejections could significantly impact timelines and costs.
• Profitability: The company has never generated revenue and expects to incur significant losses until product commercialization.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the "March 2030" liquidity projection given the high burn rate and potential for increased R&D costs.
• Fraud Recovery: Monitor updates on the recovery of the $464,000 lost to the Business Email Compromise incident.
• Regulatory Pathways: Confirm FDA acceptance of the 510(k) pathway for NASARIX™ and the De Novo pathway for PL-16, as these are critical to the business model.
• Geopolitical Exposure: Assess the potential impact of escalating Middle East conflicts on the company's ability to conduct clinical trials and retain staff in Israel.
• Warrant Exercises: Review the terms of the Series A Warrants and the impact of their cashless exercise on future dilution.